The Supreme Court’s decision Friday (June 28) overturning the Chevron doctrine could force FDA to spend more time considering the political and legal environment surrounding regulatory efforts -- hamstringing its ability to take bold action on public health priorities -- given that courts can no longer defer to federal agencies’ interpretation of vague statutes, regulatory experts say. Reshma Ramachandran, assistant professor at Yale School of Medicine, said the decision will be a major obstacle to FDA as it grapples...